UPDATE: JPMorgan Upgrades Novavax (NVAX) to Overweight

August 5, 2020 4:40 AM EDT
Get Alerts NVAX Hot Sheet
Price: $237.54 +0.11%

Rating Summary:
    8 Buy, 4 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 7 | Down: 15 | New: 24
Trade Now! 
Join SI Premium – FREE
(Updated - August 5, 2020 4:59 AM EDT)

(updating comment)

JPMorgan analyst Eric Joseph upgraded Novavax (NASDAQ: NVAX) from Neutral to Overweight with a price target of $275.00 (from $105.00).

The analyst comments "We are Overweight rated on NVAX shares. Post recent phase 1 results with NVX-CoV2373, we view immunogenicity data for the COVID-19 vaccine candidate as potentially best-inclass. Notwithstanding a number of outstanding questions with respect to phase 3 efficacy across the landscape, we believe implied valuations of phase 2 stage COVID-19 vaccine candidates to date relatively favor NVAX shares over the near-term. Elsewhere in the pipeline, we view NanoFlu to be clinically de-risked into commercialization, serving as a valuation backstop in the mid-to-high teens."

For an analyst ratings summary and ratings history on Novavax click here. For more ratings news on Novavax click here.

Shares of Novavax closed at $172.00 yesterday.


You May Also Be Interested In





Related Categories

Analyst Comments, Analyst PT Change, Hot Comments, Hot Upgrades, Upgrades

Related Entities

JPMorgan